Bianca Weißbrich

Bianca Weißbrich

Auto-generated profile, based on publicly available information

Bianca Weißbrich

Kite Pharma, Amsterdam, Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2018 in JCI Insight
Verified
Journal Article
Closed access
PDF file
BJBenjamin Y. Jin
Benjamin Y. Jin
TCTracy E. Campbell
Tracy E. Campbell
LDLindsey M. Draper
Lindsey M. Draper
SSSanja Stevanović
Sanja Stevanović
BWBianca Weissbrich
Bianca Weissbrich
CHChristian S. Hinrichs
Christian S. Hinrichs
T cell receptor (TCR) T cell therapy is a promising cancer treatment modality. However, its successful development for epithelial cancers may depend on the identification of high-avidity TCRs directed against tumor-restricted target antigens. The human papillomavirus (HPV) E7 antigen is an attractive therapeutic target that is constitutively expressed by HPV + cancers but not by healthy tissues. It is unknown if genetically engineered TCR T cells that target E7 can mediate regression of HPV + cancers. We identified an HPV-16 E7-specific, HLA-A*02:01-restricted TCR from a uterine cervix biopsy from a woman with cervical intraepithelial neoplasia. This TCR demonstrated high functional avidity, with CD8 coreceptor–independent tumor targeting. Human T cells transduced to express the TCR specifically recognized and killed HPV-16 + cervical and oropharyngeal cancer cell lines and mediated regression of established HPV-16 + human cervical cancer tumors in a mouse model. These findings support the therapeutic potential of this approach and established the basis for an E7 TCR gene therapy clinical trial in patients with metastatic HPV + cancers (NCT02858310).

3 July 2013 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
MNMagdalena Nauerth
Magdalena Nauerth
BWBianca Weißbrich
Bianca Weißbrich
RKRobert Knall
Robert Knall
TFTobias Franz
Tobias Franz
GDGeorg Dössinger
Georg Dössinger
DBDirk H Busch
Dirk H Busch
A Strep tamer-based k off rate assay identifies T cells with high protective capacity for the adoptive transfer.

3 October 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ATAna Textor
Ana Textor
KSKarin Schmidt
Karin Schmidt
PKPeter-M. Kloetzel
Peter-M. Kloetzel
BWBianca Weißbrich
Bianca Weißbrich
CPCynthia Perez
Cynthia Perez
TBThomas Blankenstein
Thomas Blankenstein
Adoptive T cell therapy (ATT) can achieve regression of large tumors in mice and humans; however, tumors frequently recur. High target peptide-major histocompatibility complex-I (pMHC) affinity and T cell receptor (TCR)-pMHC affinity are thought to be critical to preventing relapse. Here, we show that targeting two epitopes of the same antigen in the same cancer cells via monospecific T cells, which have similar pMHC and pMHC-TCR affinity, results in eradication of large, established tumors when targeting the apparently subdominant but not the dominant epitope. Only the escape but not the rejection epitope required postproteasomal trimming, which was regulated by IFN-γ, allowing IFN-γ–unresponsive cancer variants to evade. The data describe a novel immune escape mechanism and better define suitable target epitopes for ATT.